Literature DB >> 26821368

Pleural fluid procalcitonin to distinguish infectious from noninfectious etiologies of pleural effusions.

Rahul Khosla1, Shikha G Khosla2, Kenneth L Becker2, Eric S Nylen2.   

Abstract

In this study we investigate the diagnostic value of pleural fluid procalcitonin (PCT) in distinguishing infectious and noninfectious etiologies of pleural effusion. We reviewed the medical records of 75 hospitalized patients who underwent thoracentesis between 2011 and 2012. Data on pleural fluid lactate dehydrogenase (LDH), protein, albumin, cell count and differential, pH, Gram stain and culture, cytology, triglyceride, cholesterol, amylase, and PCT were collected. Data on serum LDH, protein, albumin, prothrombin time, normalized, and blood culture were also collected. Pleural effusions were classified into 2 groups, infectious and noninfectious. There were 18 infectious pleural effusions (IPE) and 57 noninfectious pleural effusions (NIPE). Median pleural fluid PCT was 1.088 ng/mL (0.312-2.940 ng/mL) in IPE and 0.123 ng/mL (0.05-0.263 ng/mL) in NIPE, with a P value < 0.0001. Pleural fluid PCT > 0.25 ng/mL had a sensitivity of 77.78% and specificity of 74.14% for diagnosing an IPE. A subgroup analysis of PCT in exudative infectious effusions versus exudative noninfectious malignant/paramalignant effusions showed higher levels in the former. PCT is a novel biomarker for diagnosing infectious pleural effusion, and it would be worthwhile to investigate the role of pleural PCT in assessing severity of illness, risk stratification, and antibiotic stewardship in hospitalized patients with pleural effusions. Journal of Hospital Medicine 2016;11:363-365. 2016 Society of Hospital Medicine.
© 2016 Society of Hospital Medicine.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26821368     DOI: 10.1002/jhm.2551

Source DB:  PubMed          Journal:  J Hosp Med        ISSN: 1553-5592            Impact factor:   2.960


  5 in total

1.  Performance of procalcitonin in diagnosing parapneumonic pleural effusions: A clinical study and meta-analysis.

Authors:  Chao He; Bo Wang; Danni Li; Huan Xu; Yongchun Shen
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889

2.  Comparing the diagnostic accuracy of semi-rigid and rigid pleuroscopy in diagnosis of exudative lymphocyte dominant pleural effusion with.

Authors:  Hamid Borsi; Mohammad Reza Farahnak; Hanieh Raji; Maryam Haddadzadeh Shooshtari; Behnam Pirhayati
Journal:  J Family Med Prim Care       Date:  2020-10-30

3.  Combined analysis of C-reactive protein in pleural fluid and serum is effective in the differential diagnosis of exudative pleural effusions.

Authors:  Shuo-Yao Qu; Yong Zhang; Shuo Wu; Ming-Ming Wang; Ling-Li Liu; Xue-Min Yang; Hui-Liang Shan; Juan-Li Yang; Pei Chen; Xin-Yu Ti
Journal:  Ann Transl Med       Date:  2021-07

4.  Nicotinamide phosphoribosyltransferase as a biomarker for the diagnosis of infectious pleural effusions.

Authors:  Jing Huang; Lun Guo; Hong-Wei Kang; Dan Lv; Wei Lin; Chao-Fen Li; Xue-Qin Huang; Qun-Li Ding
Journal:  Sci Rep       Date:  2021-10-26       Impact factor: 4.379

5.  Pleural Fluid suPAR Levels Predict the Need for Invasive Management in Parapneumonic Effusions.

Authors:  David T Arnold; Fergus W Hamilton; Karen T Elvers; Stuart W Frankland; Natalie Zahan-Evans; Sonia Patole; Andrew Medford; Rahul Bhatnagar; Nicholas A Maskell
Journal:  Am J Respir Crit Care Med       Date:  2020-06-15       Impact factor: 21.405

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.